Prodrugs: Some thoughts and current issues. J Pharm Sci 99:4755–4765.

ERRATUM Prodrugs: Some Thoughts and Current Issues. J Pharm Sci 99:4755–4765. VALENTINO J. STELLA Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047

Published online 27 July 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI 10.1002/jps.22692

Ceftibiprole medocaril and Parent: Ceftibiprole should be corrected to Ceftobiprole medocaril and Parent: Ceftobiprole Festerone should be corrected to Fesoterodine Fosamprepitant and Parent: Amprepitant should be corrected to Fosaprepitant and Parent: Aprepitant Lomesartan medoxomil and Parent: Lomesartan should be corrected to Olmesartan medoxomil and Parent: Olmesartan Neafenec should be corrected to Nepafenec Paracoxib should be corrected to Parecoxib Prulifoxacin should be corrected to Prulifloxacin Ximelamagatran should be corrected to Ximelagatran Azacitadine should be corrected to Azacitidine Clofrabine should be corrected to Clofarabine Emtriitabine should be corrected to Emtricitabine Telbividine should be corrected to Telbivudine The Original article to which this erratum refers was published in 2010;99:4755–4765. In the Original version of this paper, there were some errors with the names of drugs in Tables 1 and 3 of this paper on pages 4757, 4758 and 4760. The errors have been corrected in the list above. We regret any confusion this may have caused.

Journal of Pharmaceutical Sciences, Vol. 100, 4560 (2011) © 2011 Wiley-Liss, Inc. and the American Pharmacists Association

4560

JOURNAL OF PHARMACEUTICAL SCIENCES, VOL. 100, NO. 10, OCTOBER 2011